Heart Failure with Preserved Ejection Fraction and Obstructive Sleep Apnea: A Novel Paradigm for Additional Cardiovascular Benefit of SGLT2 Inhibitors in Subjects With or Without Type 2 Diabetes

• Published in: Advances in therapy Vol. 39; no. 11; pp. 4837 - 4846
• Main Authors: Monda, Vincenzo Maria, Gentile, Sandro, Porcellati, Francesca, Satta, Ersilia, Fucili, Alessandro, Monesi, Marcello, Strollo, Felice
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.11.2022
• Subjects: Animals; Cardiology; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Editorial; Endocrinology; Fatty Acids - pharmacology; Fatty Acids - therapeutic use; Glucose; Heart Failure - complications; Heart Failure - drug therapy; Humans; Internal Medicine; Medicine; Medicine & Public Health; Non-alcoholic Fatty Liver Disease - epidemiology; Oncology; Pharmacology/Toxicology; Rheumatology; Sleep Apnea, Obstructive - complications; Sleep Apnea, Obstructive - drug therapy; Sodium - pharmacology; Sodium - therapeutic use; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; Stroke Volume; Heart failure; T2DM; Preserved ejection fraction; NAFLD; SGLT2is; Rehabilitation; Obstructive sleep apnea; Cardiorenal protection

After examining the complex interplay between heart failure (HF) in its various clinical forms, metabolic disorders like nonalcoholic fatty liver disease (NAFLD), and obstructive sleep apnea (OSA) syndrome, in this mini-review we described possible favorable effects of sodium–glucose cotransporter 2...